What Is the Best Approach to the Nonresponding Patient with Community-Acquired Pneumonia?

Infectious Disease Clinics of North America

Volumn 27, Issue 1, 2013, Pages 189-203

  Sialer, Salvador ^a   Liapikou, Adamantia ^c   Torres, Antoni ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Biomarkers; Community acquired pneumonia; Empiric treatment; Microbiologic diagnosis; Treatment failure

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CORTICOSTEROID; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; PROCALCITONIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AGE; BACTERIAL VIRULENCE; CASE STUDY; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; DIAGNOSTIC IMAGING; DISEASE SEVERITY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FIBEROPTIC BRONCHOSCOPY; HUMAN; IMMUNE RESPONSE; INCIDENCE; LEGIONELLA; MICROBIOLOGY; NONHUMAN; PNEUMONIA SEVERITY INDEX; PROGNOSIS; PROTEIN BLOOD LEVEL; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA; RISK FACTORS; TREATMENT FAILURE;

EID: 84873538936     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2012.11.009     Document Type: Review

References (36)

1. Menéndez R., Torres A., Reyes S., et al. Initial management of pneumonia and sepsis: factors associated with improved outcome. Eur Respir J 2012, 39:156-162.
2. Ewig S., Woodhead M., Torres A. Towards a sensible comprehension of severe community-acquired pneumonia. Intensive Care Med 2011, 37:214-223.
3. Menendez R., Torres A. Treatment failure in community-acquired pneumonia. Chest 2007, 132:1348-1355.
4. Halm E.A., Fine M.J., Marrie T.J., et al. Time to clinical stability in patients hospitalized with CAP. JAMA 1998, 279:1452-1457.
5. Low D.E., Mazulli T., Marrie T. Progressive and nonresolving pneumonia. Curr Opin Pulm Med 2005, 11:247-252.
6. Kheir F., Hamdi T., Khayr W., et al. Nonresolving pneumonia. Am J Ther 2011, 18:77-79.
7. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44:S27-S72.
8. Montravers P., Fagon J.Y., Chastre J., et al. Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis 1993, 147(1):38-44.
9. Rosón B., Carratala J., Fernández-Sabé N., et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004, 164:502-508.
10. Aliberti S., Amir A., Peyrani P., et al. Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest 2008, 134:955-962.
11. Aliberti S., Blasi F. Clinical stability versus clinical failure in patients with community-acquired pneumonia. Semin Respir Crit Care Med 2012, 33(3):284-291.
12. Arancibia F., Ewig S., Martinez J.A., et al. Antimicrobial treatment failures in patients with community-acquired pneumonia. Am J Respir Crit Care Med 2000, 162:154-160.
13. Menéndez R., Torres A., Zalacaín R., et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004, 59:960-965.
14. Celis M.R., Torres A., Zalacaín R., et al. Working group for the study, diagnosis and treatment of CAP in Spain (NACE). Diagnostic methods and treatment of community-acquired pneumonia in Spain: NACE study. Med Clin (Barc) 2002, 119(9):321-326.
15. McCabe C., Kirchner C., Zhang H., et al. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia. Arch Intern Med 2009, 169(16):1525-1531.
16. Ye X., Sikirica V., Schein J.R., et al. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Clin Ther 2008, 30:358-371.
17. Ruiz-González A., Falguera M., Porcel J.M., et al. C-reactive protein for discriminating treatment failure from slow responding pneumonia. Eur J Intern Med 2010, 21:548-552.
18. Franquet T. Imaging of pneumonia: trends and algorithms. Eur Respir J 2001, 18:196-208.
19. Washington L., Palacio D. Imaging of bacterial pulmonary infection in the immunocompetent patient. Semin Roentgenol 2007, 42:122-145.
20. Pereira Gomes J.C., Pedreira W.L., Araujo E., et al. Impact of BAL in the management of pneumonia with treatment failure positivity of BAL culture under antibiotic therapy. Chest 2000, 118:1739-1746.
21. Sanyal S., Smith P.R., Saha A.C., et al. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia. Am J Respir Crit Care Med 1999, 160:346-348.
22. Menéndez R., Torres A., Zalacaiín R., et al. Guidelines for the treatment of community-acquired pneumonia. Predictors of adherence and outcome. Am J Respir Crit Care Med 2005, 172:757-762.
23. Aliberti S., Di Pasquale M., Zanaboni A.M., et al. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis 2012, 54(4):470-478.
24. Shorr A.F., Zilberberg M.D., Micek S.T., et al. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Arch Intern Med 2008, 168(20):2205-2210.
25. Wu C.L., Yang D.I., Wang N.Y., et al. Quantitative culture of endotracheal aspirates in the diagnosis of ventilator-associated pneumonia in patients with treatment failure. Chest 2002, 122(2):662-668.
26. El Solh A.A., Aquilina A.T., Gunen H., et al. Radiographic resolution of community-acquired bacterial pneumonia in the elderly. J Am Geriatr Soc 2004, 52:224-229.
27. Tomiyama N., Muller N.L., Johkoh T., et al. Acute parenchymal lung disease in immunocompetent patients: diagnostic accuracy of high-resolution CT. AJR Am J Roentgenol 2000, 174(6):1745-1750.
28. Feinsilver S.H., Fein A.M., Niederman M.S., et al. Utility of fiberoptic bronchoscopy in nonresolving pneumonia. Chest 1990, 98:1322-1326.
29. El-Solh A., Aquilina A., Dhillon R., et al. Impact of invasive strategy on management of antimicrobial treatment failure in institutionalized older people with severe pneumonia. Am J Respir Crit Care Med 2002, 166:1038-1043.
30. Moret I., Lorenzo M.J., Sarria B., et al. Increased lung neutrophil apoptosis and inflammation resolution in nonresponding pneumonia. Eur Respir J 2011, 38:1158-1164.
31. Bruns A.H., Oosterheert J.J., Hak E., et al. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J 2008, 32:726-732.
32. Menéndez R., Cavalcanti M., Reyes S., et al. Markers of treatment failure in hospitalized community acquired pneumonia. Thorax 2008, 63(5):447-452.
33. Chalmers J.D., Singanayagam A., Hill A.T. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008, 121(3):219-225.
34. Menéndez R., Martinez R., Reyes S., et al. Stability in community-acquired pneumonia: one step forward with markers?. Thorax 2009, 64(11):987-992.
35. Meijvis S.C., Hardeman H., Remmelts H.H., et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomized, double-blind, placebo-controlled trial. Lancet 2011, 137:2023-2030.
36. Confalonieri M., Urbino R., Potena A., et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005, 171:242-248.